Page 6 - Diagnostics

Dr Lal PathLabs June quarter net profit declines 52% to Rs 28.4 crore

Diagnostic services provider Dr Lal PathLabs on Friday reported a 51.94 per cent decline in its consolidated net profit at Rs 28.4 crore for the quarter ended June 30, 2020.

Fortis Malar, Lal Path Labs: Diagnostic and healthcare stocks on the charts

Stocks of diagnostic chains and hospitals have been in focus as Covid-19 pandemic spread across the country. Is it a good strategy to stay put in these counters? Here's what the charts suggest

Power Tariff relief for Chhattisgarh health set-ups combating Covid-19

Hospitals, nursing homes and diagnostic centres get 5% off on energy bill; extra relief for charitable institutions

India, US collaborating in diagnostics to fight Covid-19: Ambassador Sandhu

"India and the United States have had a long-standing productive partnership in the healthcare sector, especially between the research institutions and industries of both countries, he said

ICMR asks private diagnostic labs to test coronavirus samples for free

The shares of top diagnostic chains in the country shot up amidst volatile market conditions

Jio redux: Reliance's entry into diagnostics industry may lower prices

With bigger players making inroads, share of organised sector to increase in a fragmented market

Preventive testing, Ayushman Bharat to drive diagnostic firms' revenues

Diagnostic services companies led by Dr Lal Pathlabs, Metropolis Healthcare have outperformed the market and this trend is expected to sustain

Domestic diagnostics manufacturers want govt to go slow on prices

But on the other side are public health scholars who caution that not having price control could lead manufacturers to form cartels

PerkinElmer acquires autoimmune testing firm Euroimmun for $1.3 billion

Deal to boost PerkinElmer's growth by adding leading positions in autoimmune & allergy diagnostics